Edward Nash
Stock Analyst at Canaccord Genuity
(4.06)
# 568
Out of 5,042 analysts
79
Total ratings
54.93%
Success rate
12.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Downgrades: Hold | $73 → $54 | $53.77 | +0.43% | 7 | Oct 9, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $28 | $9.14 | +206.35% | 2 | Oct 2, 2025 | |
| IVA Inventiva | Maintains: Buy | $20 | $6.20 | +222.58% | 3 | Sep 30, 2025 | |
| CORT Corcept Therapeutics | Maintains: Buy | $140 | $72.52 | +93.05% | 10 | Sep 25, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $62 | $26.72 | +132.04% | 3 | Sep 17, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $428 → $526 | $421.50 | +24.79% | 11 | Sep 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $45 → $47 | $28.06 | +67.50% | 10 | Apr 10, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 | $1.82 | +394.51% | 2 | Feb 26, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Hold | $4 | $1.81 | +120.99% | 2 | Feb 10, 2025 | |
| APGE Apogee Therapeutics | Initiates: Buy | $89 | $53.32 | +66.92% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $14 | $5.81 | +140.96% | 6 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $1.19 | +572.27% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $9.19 | +84.98% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $2.39 | -16.32% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $1.38 | +12,943.48% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $33.53 | +144.56% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $80 | $4.07 | +1,865.60% | 3 | Sep 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $61.01 | -21.32% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $5.48 | +11,761.31% | 1 | Nov 8, 2017 |
Akero Therapeutics
Oct 9, 2025
Downgrades: Hold
Price Target: $73 → $54
Current: $53.77
Upside: +0.43%
Sagimet Biosciences
Oct 2, 2025
Maintains: Buy
Price Target: $28
Current: $9.14
Upside: +206.35%
Inventiva
Sep 30, 2025
Maintains: Buy
Price Target: $20
Current: $6.20
Upside: +222.58%
Corcept Therapeutics
Sep 25, 2025
Maintains: Buy
Price Target: $140
Current: $72.52
Upside: +93.05%
Celldex Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $62
Current: $26.72
Upside: +132.04%
Madrigal Pharmaceuticals
Sep 12, 2025
Maintains: Buy
Price Target: $428 → $526
Current: $421.50
Upside: +24.79%
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45 → $47
Current: $28.06
Upside: +67.50%
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $1.82
Upside: +394.51%
Pliant Therapeutics
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.81
Upside: +120.99%
Apogee Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $53.32
Upside: +66.92%
Aug 12, 2024
Maintains: Buy
Price Target: $15 → $14
Current: $5.81
Upside: +140.96%
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.19
Upside: +572.27%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $9.19
Upside: +84.98%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.39
Upside: -16.32%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $1.38
Upside: +12,943.48%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $33.53
Upside: +144.56%
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $4.07
Upside: +1,865.60%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $61.01
Upside: -21.32%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $5.48
Upside: +11,761.31%